The grant of a U.S. Patent for phosphoramidate derivatives for cancer treatment is a significant positive development for NuCana Plc. It not only validates the company's research and development efforts but also potentially opens up new avenues for the treatment of cancer, especially in cases where patients show resistance to existing treatments. The substantial increase in trading volume and the sharp rise in stock price reflect the market's optimistic view on this news. While the company does not pay dividends or have a buyback program, such innovations can significantly enhance shareholder value through stock price appreciation.